Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

Please provide your email address to receive an email when new articles are posted on . The treatment group had reductions in FeNO 1 week after a single dose. Reductions were significant compared with ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed. After receiving ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the phase ...

Patients treated for uncontrolled mild asthma had high symptom burden affecting their daily life but most had no ...

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...

APG808 was well-tolerated and there were no severe adverse events. Credit: Explode via Shutterstock. At the 2025 European Respiratory Society (ERS) International Congress takig place in Amsterdam, the ...